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Tolerability of induction chemotherapy dosing practices in acute
myeloid leukemia patients
Kaylene M. Peric
David J. Reeves

Abstract
For patients with high body surface areas (BSA), differing chemotherapy dosing strategies have
been utilized in attempts to reduce toxicity. In a retrospective evaluation, we compared the effects
of chemotherapy dosing in acute myeloid leukemia patients with high BSA (>2 m2) who received
capped doses (n = 12) to those who received uncapped doses (n = 24), and to patients with
BSA ≤ 2 m2 (n = 42). There were no statistically significant differences among groups
(BSA ≤ 2 m2, BSA > 2 m2 capped, and BSA > 2 m2 uncapped) in the incidences of febrile
neutropenia (85.7, 66.7, and 75.0%, respectively, p = 0.29), bacteremia (19.0, 8.3, and 16.7%,
respectively, p = 0.68), mucositis (42.8, 50.0, and 41.7%, respectively, p = 0.88) or
nausea/vomiting (47.6, 33.3, and 37.5, respectively, p = 0.57). Results suggest delivery of
unadjusted chemotherapy based on actual body weight is likely safe in hematological
malignancies.

1. Introduction
Chemotherapy agents are known to have narrow therapeutic indices, where a small difference in
dose could potentially lead to poor treatment outcomes or increased toxicity [1], [2], [3] and [4].
This makes dose selection challenging, especially since many of the variable patient-related factors
affecting the metabolism and clearance of these drugs are difficult to predict [3], [5] and [6]. It is
often assumed that larger patients require higher doses than smaller patients to provide similar
drug concentrations and outcomes [4]. Body surface area (BSA) has traditionally been and remains
the most frequent measure used to determine chemotherapy doses [7], [8] and [9]. This method of
dosing leads to difficulties when heights and/or weights are at extremes [3] and [6]. Given the rise
in prevalence of obesity worldwide over the past few decades [10], selecting doses in this group is
a common struggle due to concerns for potential toxicity associated with larger doses of
chemotherapy when actual body weight is used to determine dosing. Thus, various dosing
strategies for the obese population have been utilized amongst practicing physicians and
institutions [11], [12] and [13]. Some of these include use of an adjusted body weight, ideal body
weight, or capping the BSA at 2 m2[4], [11], [12], [13], [14] and [15]. As result of this empiric
weight modification, up to 40% of obese patients have received intentionally reduced
chemotherapy dosages in an attempt to reduce the potential toxic effects [16].
In an attempt to clarify dosing strategies for clinicians, the American Society of Clinical Oncology
(ASCO) developed a clinical guideline in April 2012, recommending the use of full-dose
chemotherapy based on actual body weight for obese cancer patients specifically when the
treatment goal is cure of the disease [17]. However, the guideline recommendations are based on
studies in solid tumor malignancies and did not include obese patients receiving therapy for
hematological malignancies. Patient weight in the leukemic population has been assessed in
multiple studies in terms of impact on survival and toxicity; however, empiric dosing strategies to
mitigate patient risk for toxicity (dose capping) has only been evaluated in one prior study [18],
[19], [20] and [21]. The purpose of this study was to evaluate chemotherapy dosing in adult acute
myeloid leukemia (AML) patients receiving induction treatment and determine if there are
differences in toxicities when doses in patients with BSA > 2 m2 are empirically capped, compared
to when they are not capped, and to patients with BSA values ≤2 m2.
2. Methods
2.1. Study patients
This retrospective, single center study was approved by the local Institutional Review Board. Adult
patients with a diagnosis of AML that completed standard induction chemotherapy consisting of
an anthracycline (idarubicin or daunorubicin) daily for 3 days in combination with continuous
infusion cytarabine for 7 days between January 2008 and August 2013 were included in the study.
Patients whom received radiation therapy or were pregnant during therapy were excluded.
2.2. Data collection and analysis
Demographic and clinical characteristics were collected from the electronic health record for all
eligible patients, which included age, sex, height, weight, and calculated BSA value.

Chemotherapy agents and their respective doses administered, in addition to whether G-CSF was
used during patients’ hospital stay were also identified.
The following adverse effects were collected: episodes of febrile neutropenia, documented
mucositis, documented bacteremia, and documented nausea and vomiting. Additional outcomes
such as day of neutrophil recovery (ANC > 500 cell/mcL) post chemotherapy, length of hospital
stay, and attainment of complete remission post induction chemotherapy as defined by the
International Working Group (IWG) criteria (bone marrow blasts < 5%, ANC > 1000 mcL−1,
platelet count > 100,000 mcL−1), were also collected [22].
BSA values were calculated based on patient height and weight using the Mosteller formula,
([height (cm) × weight (kg)]/3600)1/2[9]. Patients were categorized into three groups based on their
calculated BSA and the BSA utilized to dose the patient: those with BSA > 2 m2 whom received
empirically capped chemotherapy doses (capped group), those with BSA > 2 m2 whom received
full actual body weight calculated doses (uncapped group), and those with BSA ≤ 2 m2. The
BSA > 2 m2 capped group was compared to both the BSA > 2 m2 uncapped group, and to the
BSA ≤ 2 m2 group. The BSA > 2 m2 uncapped group was also compared to the BSA ≤ 2 m2 group.
2.3. Outcome measures
The primary end point was the overall incidence of adverse effects during admission, which
included: occurrence of febrile neutropenia, documented mucositis, documented bactermia, and
documented episodes of nausea or vomiting. Secondary endpoints were time (days) to neutrophil
recovery (ANC > 500 cells/mcL) after the start of chemotherapy, length of hospital stay, and
complete remission following induction chemotherapy.
2.4. Statistical methods
Continuous variables between groups were compared using Student's t-test (or non parametric
Mann–Whitney U tests, dependent upon the parametric nature of the data). Categorical data was
compared between groups using a Fisher's exact test or a Pearson chi-square test, as appropriate.
These analyses were performed using SPSS 21.0 (Statistical Package for the Social Sciences,
Chicago, IL). A two sided p-value <0.05 was considered significant. Univariate comparisons on
demographic and clinical variables were made to assess the comparability between the three
groups. Incidences of adverse effects were analyzed univariately using Fisher's exact tests. Binary
logistic regression analyses were used to obtain adjusted odds ratios of the significant predictors
of adverse events and the attainment of complete remission following induction chemotherapy.
Predictors accounted for in the regression included BSA, dosing strategy (capped/uncapped), sex,
age, history of prior chemotherapy, receipt of granulocyte-colony stimulating factor and
chemotherapy agent (daunorubicin/idarubicin). Time to neutrophil recovery and hospital lengths
of stay were analyzed using Kaplan Meier survival analysis and Cox regression.

3. Results
3.1. Baseline and treatment characteristics
Of the 78 patients included in the evaluation, 42 had a BSA ≤ 2 m2, 24 had a BSA > 2 m2 and
received uncapped actual body weight (ABW) calculated doses, and 12 had BSA values >2 m2
and received capped doses. Patient demographics and treatment characteristics are provided in
Table 1. Excluding the expected differences in average weight, height and BSA, there were no
significant differences in patient characteristics between the groups except for gender. A higher
proportion of patients were male in the BSA > 2 m2 groups. The average age of all evaluated
patients was 56.5 years and few patients (10.3%) had previous chemotherapy exposure. All
patients completed standard induction chemotherapy with an anthracycline and cytarabine. The
type of anthracycline agent received and dosages (daunorubicin, 30–90 mg/m2; idarubicin,
12 mg/m2; cytarabine 100–200 mg/m2) were not different among the groups. The actual capped
dose administered to patients with a BSA > 2 was on average 10.5% lower for idarubicin, 13.3%
lower for daunorubicin, and 11.4% lower for cytarabine then they would have been had their doses
been uncapped.

Table 1. Baseline and treatment characteristics.

Mean age (years)
Male, n (%)
Mean BSA, m2 (range)
Mean weight (kg)
Mean height (cm)
Previous chemotherapy exposure, n
(%)
Receipt of granulocyte colony
stimulating factor (G-CSF), n (%)
Median daunorubicin dosage (mg/m2)
[IQR]
Median idarubicin dosage (mg/m2)
[IQR]
Median cytarabine dosage (mg/m2)
[IQR]

BSA ≤ 2 m2
(n = 42)
58.9
15 (35.7)
1.78 (1.45–
1.98)
70.3
165.2

BSA > 2 m2
capped (n = 12)
53.8
8 (66.7)

BSA > 2 m2
puncapped (n = 24) Value
53.7
0.61
18 (75)
0.005

2.25 (2.05–2.85)

2.20 (2.02–2.73)

0.001*

107.9
176.8

100.6
178.6

0.001*
0.001*

3 (7.1)

2 (16.2)

3 (12.5)

0.57

12 (28.6)

1 (8.3)

9 (37.5)

0.19

60 [45.0]

52.5 [32.5]

60 [20.0]

0.98

12 [0]

12 [0]

12 [0]

1.00

100 [100]

100 [100]

100 [100]

0.74

BSA: body surface area, IQR: interquartile range.
*Statistically significant difference between BSA ≤ 2 m2 and BSA > 2 m2 groups. No statistically
significant difference between BSA > 2 capped and BSA > 2 uncapped groups in BSA (p = 0.36), weight
(p = 0.21), and height (p = 0.54).

3.2. Outcomes
There were no significant differences in rates of chemotherapy related adverse effects among
patients with BSA ≤ 2 m2, BSA > 2 m2 that received capped doses, and BSA > 2 m2 that received
uncapped doses (Table 2). The most common adverse effect was febrile neutropenia, which
occurred in 85.7%, 66.7% and 75.0% (p = 0.29) of patients, respectively. Thirteen of the 78
patients (16.7%) had documented bacteremia during their admission with no significant difference
in incidence among the groups (19.0%, 8.3%, 16.7; p = 0.68). The rates of documented mucositis
were similar between groups (p = 0.88), affecting 42.8% of patients in the BSA ≤ 2 m2 group,
50.0% in the BSA > 2 m2 capped group, and 41.7% in the BSA > 2 m2 uncapped group. The
reported incidence of nausea and/or vomiting was 47.6%, 33.3%, and 37.5%, respectively
(p = 0.57).

Table 2. Incidence of adverse effects.
BSA ≤ 2 m2
(n = 42)
36 (85.7)
20 (47.6)
18 (42.8)
8 (19.0)

Febrile neutropenia, n (%)
Nausea/vomiting, n (%)
Mucositis, n (%)
Bacteremia, n (%)
Median time to ANC > 500
25.5
cells/mcL (days)
Median length of hospitalization,
31.5
days
Complete remission (CR)
Number evaulable
CR, n (%)

37
17 (45.9)

BSA > 2 m2 capped
(n = 12)
8 (66.7)
4 (33.3)
6 (50.0)
1 (8.3)

BSA > 2 m2 uncapped
(n = 24)
18 (75.0)
9 (37.5)
10 (41.7)
4 (16.7)

pValue
0.29
0.57
0.88
0.68

24.5

29.5

0.48

27.5

35.0

0.34

10
7 (70.0)

22
11 (50%)

0.4

BSA: body surface area, ANC: absolute neutrophil count, std. dev: standard deviation.

The mean time to neutrophil recovery was longest for the patients that received uncapped doses,
but not significantly different (p = 0.48) among the three groups (Fig. 1). It took a median of 25.5
days for patients with BSA ≤ 2 m2 to recover their neutrophils compared to 24.5 days for those
with BSA > 2 m2 that received capped doses and 29.5 days for those with BSA > 2 m2 that received
uncapped doses. Median length of hospital stay did not significantly differ among the three groups
(31.5 days, 27.5 days, 35.0 days, respectively, p = 0.34).

Fig. 1. Days to neutrophil recovery post induction chemotherapy.
Based on the post-induction analysis of complete remission (CR), there was no significant
difference in the incidence of CR among all the groups. Of the 37 patients in the BSA ≤ 2 m2 group
evaluable for response, 17 (45.0%) achieved a CR. Similarly, 50.0% of patients with BSA > 2 m2
that received uncapped doses (22 evaluable patients) and 70.0% of those that received capped
doses (10 evaluable patients) achieved a CR. In total, 5 patients experienced early death (prior to
assessment of response).
Utilizing multivariate analysis, BSA and dosing strategy (capped/uncapped) were not found to be
significantly associated with toxicity rates (febrile neutropenia, bacteremia, mucositis,
nausea/vomiting) or post-induction complete remission rate. Age was the only significant predictor
of nausea/vomiting (odds ratio 0.96, 95% CI 0.92–0.99, p = 0.02).
4. Discussion
As the prevalence of obesity continues to increase worldwide [10], clinicians will likely encounter
a greater proportion of cancer patients with high BSA values. Determining the most appropriate
strategy for dosing chemotherapy in this population is important to ensure effective treatment
while avoiding unnecessary toxicities.
Much of the current knowledge of dosing practices and chemotherapy toxicity effects in obesity
is based on evidence in breast cancer. However, a few studies are available in the leukemic
population in which body weight has been reported to effect outcomes. A study of 97 adults with
AML over the age of 60 years investigated the association between baseline BMI and overall
survival [19]. Patients with a BMI greater than 30 had a lower hazard ratio for mortality compared
to those with a BMI less than 25 (HR 2.14; 95% CI 1.21 to 3.77). Patients in this study were dosed
based on actual body weight without any dose reductions in the obese population. Similarly, a
study of 1974 adult patients with AML showed CR rates were higher with increasing BMI (OR
1.03, p = 0.004) and that there was no association between toxicity and BMI [20]. Patients were
treated with doses based on actual BSA (one patient received treatment based on ideal body

weight). In yet another study (n = 247), the toxicity and efficacy of actual body weight based
chemotherapy doses were compared amongst underweight/normal (BMI < 18.5–24.9 kg/m2),
overweight (BMI 25–29 kg/m2), and obese (BMI > 30 kg/m2) AML patients that received standard
induction treatment [18]. Results showed no significant differences in toxicity, including days to
neutrophil recovery, incidence of documented bacteremia and heart failure among normal,
overweight and obese patient groups. In addition, complete remission rates were also similar
among the groups. Authors concluded that use of full actual body weight based doses is justified
even at extremes of weight. Overall, these assessments were based on patients who received nondose reduced chemotherapy regimens and excluded those with empirically adjusted doses.
One study investigating the impact of obesity on the efficacy and toxicity of induction
chemotherapy in AML patients (n = 63) did describe the impact of dose reduction in the obese
population [21]. Obesity was defined as ≥30% above ideal body weight. Seven of the 21 obese
patients received a dose reduction (1 was reduced for renal impairment, 4 used an adjusted weight
BSA, and 2 capped the BSA at 2). No differences were identified in toxicity between those
receiving a dose reduction and those receiving unreduced doses based on actual body weight.
Additionally, there was no association in the total population between obesity and toxicity,
including neutrophil recovery by 30 days (OR 1.11, p = 0.43) and platelet recovery by 30 days
(OR 1.12, p = 0.36).
Our evaluation showed similar results, although patients were analyzed based on their BSA and
respective dosing strategy used, rather than BMI or precent above ideal body weight. We found
no significant differences in the incidences of any of the evaluated chemotherapy related adverse
effects, time to neutrophil recovery, or lengths of hospitalization among patients with BSA ≤ 2 m2,
those with BSA > 2 m2 that received uncapped doses, and those with BSA > 2 m2 that received
intentionally capped doses. Additionally, assessment of response to determine efficacy of the
received induction therapy demonstrated no differences in rates of CR after bone marrow recovery
between the groups.
Interestingly, patients with BSA ≤ 2 m2 experienced a greater incidence (though non-significant)
of febrile neutropenia, nausea/vomiting, and documented bacteremia than patients with
BSA > 2 m2 regardless of dosing strategy used. Similar results have been shown in previous studies
performed in breast cancer patients suggesting larger patients may be underdosed even with full,
actual body weight based doses [1] and [13].
Overall, our patient population recovered their neutrophils a few days sooner than the previous
study of AML patients (27.3 vs 33.0 days, respectively) [20]. Although not statistically significant,
it took slightly longer to recover neutrophil counts for those patients that received uncapped doses
(29.6 days) implying a possible greater myelotoxic effect compared to those who received capped
doses and those with BSA ≤ 2 m2 (23.6 and 26.7 days), respectively. However, there was no
correlation with neutrophil recovery time and average length of hospitalization as patients in the
BSA ≤ 2 m2 group recovered their counts sooner than the uncapped group, but had a nonsignificant longer hospital stay.
Limitations include the retrospective design of the study as some patients had incomplete and/or
missing data if they received follow-up outside the institution. Though analysis of the data showed

that there were no significant differences between groups, the results may be limited by the small
sample size and may lack the power to detect more minute differences. Most importantly,
prognostic factors were not taken into account when assessing response, making efficacy difficult
to assess and compare across groups. In addition, the primary outcome was the incidence of
adverse effects, which relied on physician interpretation and documentation in the medical record.

5. Conclusion
The use of ABW based doses in patients with BSA > 2 m2 was not associated with an increase in
toxicity as there were no significant differences in the incidence of adverse effects among the
BSA > 2 m2 capped, BSA > 2 m2 uncapped, and BSA ≤ 2 m2 groups. Attempts to reduce toxicity
by empirically reducing chemotherapy doses for patients with high BSA values may not be
justified as no significant benefit was seen in regard to toxicity or neutrophil recovery in patients
with BSA > 2 m2 who received capped doses. These results further support the safety of ASCO
recommendations for the use of uncapped/unadjusted chemotherapy doses in the hematological
malignancy setting.
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